US20120316217A1 - combination for the treatment of osteoarthritis - Google Patents

combination for the treatment of osteoarthritis Download PDF

Info

Publication number
US20120316217A1
US20120316217A1 US13/517,307 US201013517307A US2012316217A1 US 20120316217 A1 US20120316217 A1 US 20120316217A1 US 201013517307 A US201013517307 A US 201013517307A US 2012316217 A1 US2012316217 A1 US 2012316217A1
Authority
US
United States
Prior art keywords
osteoarthritis
formulation
months
treatment
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/517,307
Other languages
English (en)
Inventor
Franco Conti
Edoardo Carlo Maria Conti
Giovanni Federico Maria Conti
Arborio Mella Isabella
Francesco Saverio Dioguardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROFESSIONAL DERMA SA
Original Assignee
Professional Dietetics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics SpA filed Critical Professional Dietetics SpA
Assigned to PROFESSIONAL DIETETICS S.R.L. reassignment PROFESSIONAL DIETETICS S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARBORIO MELLA (LEGAL REPRESENTATIVE AND HEIRESS OF DECEASED INVENTOR FRANCO CONTI), ISABELLA, CONTI (DECEASED), FRANCO, CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), EDOARDO CARLO MARIA, CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), GIOVANNI FEDERICO MARIA, DIOGUARDI, FRANCESCO SAVERIO
Publication of US20120316217A1 publication Critical patent/US20120316217A1/en
Assigned to PROFESSIONAL DERMA SA reassignment PROFESSIONAL DERMA SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PROFESSIONAL DIETETICS S.P.A.
Assigned to PROFESSIONAL DIETETICS S.P.A. reassignment PROFESSIONAL DIETETICS S.P.A. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PROFESSIONAL DIETETICS S.R.L.
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79Polymers of vinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action

Definitions

  • the present invention relates to a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, for the treatment of osteoarthritis, in particular for patellofemoral or femorotibial osteoarthritis of the knee, osteoarthritis of the hip and osteoarthritis of the shoulder.
  • Osteoarthritis is the most common joint disease among the rheumatic disorders affecting the Western world. It is a chronic degenerative joint disease which may be diffuse or localised, affecting the cartilage of the diarthrodial joints, where the normal metabolic process of the chondrocytes is impaired, leading to softening, fibrillation, ulceration and subsequent sclerosis of the subchondral bone, and in the final stages to new bone formation and subchondral cysts.
  • Osteoarthritis which mainly affects women, most frequently involves the patellofemoral joint, the femorotibial joint, the hip and the shoulder. Osteoarthritis of the knee, or gonarthritis, is particularly frequent and disabling.
  • the clinical picture is initially dominated by characteristically mechanical pain at the anterior or anteromedial site, which is attenuated by rest. After lengthy inactivity, for example in the mornings or after sitting for a long time, painful post-inactivity spasms may be experienced. However, they are shortlived, and attenuated by walking. Pain may be triggered by using stairs, especially walking downstairs, squatting, especially in the case of patellofemoral osteoarthritis, or lengthy use of vehicle pedals.
  • knee osteoarthritis requires a combination of pharmacological and other treatments, which must be tailored to the patient's requirements on the basis of local risk factors (obesity, mechanical factors, physical activity), general risk factors (age, comorbidity, multiple drug therapy), pain intensity levels and degree of disability, signs of inflammation (effusion), location and degree of structural damage.
  • local risk factors ovality, mechanical factors, physical activity
  • general risk factors age, comorbidity, multiple drug therapy
  • pain intensity levels and degree of disability signs of inflammation (effusion), location and degree of structural damage.
  • Non-pharmacological treatment of knee osteoarthritis should include rehabilitation programmes, physical exercise, the use of aids (walking sticks, insoles or knee braces) and weight loss, where necessary.
  • the first-line medicament for the treatment of pain in knee osteoarthritis is paracetamol, which is used at doses lower than or equal to 3 gm/day in addition to other osteoarthritis drugs.
  • Topical applications of NSAIDs or capsaicin can be a useful treatment if used for short periods, especially for patients who refuse or are unable to take oral medicaments.
  • NSAIDs are considered for patients who fail to respond to paracetamol and patients at gastrointestinal risk; in that case, conventional COXIBs or NSAIDs associated with proton pump inhibitors are used.
  • Opioid analgesics represent useful alternatives in patients for whom NSAIDs or COXIBs are contraindicated because they are ineffective or poorly tolerated.
  • Other drugs used are those which, when administered by the oral or intra-articular route, reduce the clinical symptoms at varying rates, by different methods from analgesics or NSAIDs.
  • This group consists of two different categories: slow-acting symptomatic medicaments for osteoarthritis, and medicaments able to modify the progress of osteoarthritis.
  • Glucosamine sulphate, chondroitin sulphate, soya and avocado extracts, diacerein, hyaluronic acid and S-adenosylmethionine belong to the first group.
  • These medicaments have a direct action on the chondrocytes and synoviocytes and consequently have beneficial effects on the cartilage structure. Their efficacy against the symptoms starts slowly (1-2 weeks) but lasts for a long time: up to two months after discontinuance of the treatment.
  • Intra-articular injection of cortisones with a long-lasting action is indicated for acute joint pain, especially if it is associated with intra-articular effusions.
  • intra-articular compositions comprising glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, lysine and/or leucine, is effective in the treatment of osteoarthritis, especially as regards the aspect of pain management.
  • compositions according to the invention have a significant effect on pain reduction and improvement in the joint function, and consequently on the patient's quality of life. This effect is long-lasting, even after the treatment is discontinued (up to two months).
  • compositions according to the invention therefore provides a useful treatment for osteoarthritis, especially in pain management, offering fast, effective pain reduction.
  • the present invention therefore relates to a combination comprising:
  • osteoarthritis in particular knee osteoarthritis.
  • the natural or synthetic viscosity-controlling polymer is selected from hyaluronic acid or a salt thereof, polyvinylpyrrolidone, and cellulose derivatives.
  • the natural or synthetic viscosity-controlling polymer is hyaluronic acid or a salt thereof.
  • aminoacids are present in the L form.
  • the intra-articular compositions according to the invention will contain the various active constituents in the following composition ranges by weight:
  • compositions according to the invention are formulated suitably for intra-articular administration in the form of reconstitutable powders, solutions and the like, and will be prepared according to conventional methods well known in pharmaceutical technology, such as those described in Remington's Pharmaceutical Handbook, Mack Publishing Co., N.Y., USA, using excipients suitable for their final use.
  • the purpose of the trial was to evaluate the therapeutic efficacy of intra-articular administration of a composition according to the invention in patients suffering from primary osteoarthritis of the knee by assessing the thickness of the cartilage, the intensity of pain and the patients' quality of life before and after treatment.
  • composition according to the invention used for the trial consisted of 2 bottles: bottle A, containing sodium hyaluronan in aqueous solution; and bottle B, containing a freeze-dried powder based on glycine (182 mg), L-proline (150 mg), L-lysine (35 mg) and L-leucine (21 mg).
  • the product Before administration, the product must be reconstituted (the freeze-dried powder in bottle B is dissolved in the solution contained in bottle A) to provide a transparent solution containing no particulate matter.
  • the area to be treated was disinfected, and then anaesthetised with an anaesthetic cream to be applied 30 minutes before the operation.
  • the infiltrations were repeated once a week for 5 weeks.
  • VAS visual analogue scale
  • Thickness of knee joint cartilage in the central, medial and lateral compartment by means of an ultrasound scan (performed with a Philips Envisor 250 ultrasound system with multifrequency linear probe from 5 to 13 MHz).
  • composition according to the invention was well tolerated, with no local or systemic allergic reactions.
  • results of the clinical evaluation are set out in Tables I and II.
  • the mean pain value (VAS) evaluated by patients at the beginning of the trial was 58.03 ( ⁇ 8.31); after three months, the mean value was 28.07 ( ⁇ 8.55), a percentage decrease of 58% (p ⁇ 0.05); and after six months the mean value had fallen to 16.20 ( ⁇ 9.28) (p ⁇ 0.05).
  • the mean pain value (VAS) evaluated by the doctors at the beginning of the trial was 56.18 ( ⁇ 9.66); after three months, the mean value was 22.03 ( ⁇ 7.32), a percentage decrease of 54% (p ⁇ : 0.05); after six months the mean value had fallen still further, to 9.11 mm ( ⁇ 6.97), a percentage decrease of 71% compared with baseline (p ⁇ 0.05).
  • the mean thickness of the central cartilage after three months (0.29 mm ⁇ 0.07) was not significant, whereas after six months (0.31 ⁇ 0.11 mm) there was a statistically significant increase compared with the baseline value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
US13/517,307 2009-12-21 2010-12-13 combination for the treatment of osteoarthritis Abandoned US20120316217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A002256A IT1397522B1 (it) 2009-12-21 2009-12-21 Uso di una combinazione per il trattamento dell'osteoartrosi
ITMI2009A002256 2009-12-21
PCT/EP2010/069451 WO2011076596A1 (en) 2009-12-21 2010-12-13 A combination for the treatment of osteoarthritis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069451 A-371-Of-International WO2011076596A1 (en) 2009-12-21 2010-12-13 A combination for the treatment of osteoarthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/947,538 Continuation US9040575B2 (en) 2009-12-21 2013-07-22 Combination for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
US20120316217A1 true US20120316217A1 (en) 2012-12-13

Family

ID=42342759

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/517,307 Abandoned US20120316217A1 (en) 2009-12-21 2010-12-13 combination for the treatment of osteoarthritis
US13/947,538 Active 2031-01-03 US9040575B2 (en) 2009-12-21 2013-07-22 Combination for the treatment of osteoarthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/947,538 Active 2031-01-03 US9040575B2 (en) 2009-12-21 2013-07-22 Combination for the treatment of osteoarthritis

Country Status (13)

Country Link
US (2) US20120316217A1 (pt)
EP (1) EP2515897B1 (pt)
JP (1) JP2013515024A (pt)
KR (1) KR20120095451A (pt)
CN (1) CN102665708B (pt)
BR (1) BR112012015124B1 (pt)
CA (1) CA2785116C (pt)
ES (1) ES2447829T3 (pt)
IT (1) IT1397522B1 (pt)
PL (1) PL2515897T3 (pt)
RS (1) RS53197B (pt)
RU (1) RU2560844C2 (pt)
WO (1) WO2011076596A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2549436C1 (ru) * 2014-06-06 2015-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский Государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВРО РостГМУ Минздрава России) Способ лечения больных плечелопаточным периартрозом
JPWO2020009191A1 (ja) * 2018-07-04 2021-08-02 味の素株式会社 高齢動物の疼痛緩和用アミノ酸含有組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249065A1 (en) * 2005-10-26 2008-10-09 Franco Conti Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304191B1 (it) * 1998-12-18 2001-03-08 Solartium Establishment Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia odontoiatrica sia sotto forma iniettabile che in
IT1318556B1 (it) * 2000-06-07 2003-08-27 Solartium Establishment Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni
YU75003A (sh) * 2002-01-11 2006-08-17 Matthias Rath Nutriciona farmaceutska formulacija koja uključuje polifenole i upotreba u tretmanu kancera
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US20060029647A1 (en) * 2004-02-09 2006-02-09 Friesen Kim G Composition and method for use in cartilage affecting conditions
WO2006067608A1 (en) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
ITMI20051230A1 (it) * 2005-06-29 2006-12-30 Pharmaperoducts Uk Ltd Composizioni farmaceutiche e cosmetiche contenenti colostro tocoferoli ossido di zinco e acido ialuronico
ITMI20052037A1 (it) * 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche cicatrizzanti sotto forma di polvere sterile a base di amminoacidi e sodio ialuronato
JP2007161688A (ja) * 2005-12-16 2007-06-28 Hiroshima Univ 軟骨生成促進剤
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
JP2009120512A (ja) * 2007-11-13 2009-06-04 Nitta Gelatin Inc 関節軟骨再生促進剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249065A1 (en) * 2005-10-26 2008-10-09 Franco Conti Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate

Also Published As

Publication number Publication date
EP2515897A1 (en) 2012-10-31
CA2785116A1 (en) 2011-06-30
US20130310437A1 (en) 2013-11-21
RS53197B (en) 2014-06-30
RU2012125823A (ru) 2013-12-27
ITMI20092256A1 (it) 2011-06-22
BR112012015124A8 (pt) 2017-12-26
IT1397522B1 (it) 2013-01-16
KR20120095451A (ko) 2012-08-28
US9040575B2 (en) 2015-05-26
EP2515897B1 (en) 2013-12-04
PL2515897T3 (pl) 2014-05-30
ES2447829T3 (es) 2014-03-13
RU2560844C2 (ru) 2015-08-20
BR112012015124A2 (pt) 2017-06-20
JP2013515024A (ja) 2013-05-02
CA2785116C (en) 2017-09-05
BR112012015124B1 (pt) 2021-06-15
CN102665708A (zh) 2012-09-12
CN102665708B (zh) 2014-11-05
WO2011076596A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
US20220152059A1 (en) Methods and compositions for treating various disorders
AP476A (en) Eliminating maximum adjacent cut specification restrictions for telescoping pins
Mei-Dan et al. Treatment of osteoarthritis of the ankle by intra-articular injections of hyaluronic acid: a prospective study
US20200170963A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
AU2009304002B2 (en) A medicinal product and treatment
US9040575B2 (en) Combination for the treatment of osteoarthritis
Yakushin et al. Comparison of the efficacy and safety of ketoprofen plaster and diclofenac plaster for osteoarthritis-related knee pain: A multicenter, randomized, active-controlled, open-label, parallel-group, phase III clinical trial
RU2268052C2 (ru) Средство для лечения воспалительных и дегенеративных заболеваний суставов (варианты), способ лечения воспалительных и дегенеративных заболеваний суставов (варианты) и устройство для доставки лекарственного средства к пораженному участку
CN105982911A (zh) 一种氨基葡萄糖和玻璃酸钠组合的高粘弹性注射液的制备方法
KR20230018481A (ko) 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여
TW200927151A (en) Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof
Khongwir et al. A comparative study of the results of conservative therapy, intra-articular steroid injection therapy and intra-articular hyaluronic acid injection therapy in primary osteoarthritis of knee: a prospective study in Eastern Indian population
RU2777213C1 (ru) Способ лечения болезней суставов
CN117957004A (zh) 用于整形外科领域的包含透明质酸钠和氨基酸的组合物
Gosikonda et al. Role of viscosupplementation in the management of primary osteoarthritis knee
US20190021995A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
WO2016092377A2 (ru) Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов, её применение и способ лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника
Chowdhury Role of Glucosamine Sulphate, Chrondoitin Sulphate & Vitamin C in Enhancing Chrondoprotective Effects and Management of Pain in Osteoarthritis

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROFESSIONAL DIETETICS S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONTI (DECEASED), FRANCO;CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), EDOARDO CARLO MARIA;CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), GIOVANNI FEDERICO MARIA;AND OTHERS;REEL/FRAME:028409/0641

Effective date: 20120605

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PROFESSIONAL DERMA SA, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROFESSIONAL DIETETICS S.P.A.;REEL/FRAME:036665/0806

Effective date: 20150721

Owner name: PROFESSIONAL DIETETICS S.P.A., ITALY

Free format text: CHANGE OF NAME;ASSIGNOR:PROFESSIONAL DIETETICS S.R.L.;REEL/FRAME:036700/0353

Effective date: 20150630